In vitro antifungal activities of sulfa drugs against clinical isolates of Aspergillus and Cryptococcus species

Japanese Journal of Medical Mycology

Volumn 48, Issue 1, 2007, Pages 47-50

  Hanafy, Ahmed ^a   Uno, Jun ^a   Mitani, Hiroki ^a   Kang, Yingqian ^a   Mikami, Yuzuru ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Aspergillus; Cryptococcus; In vitro; Sulfa drugs; Susceptibility test

Indexed keywords

SULFADIAZINE; SULFADIMETHOXINE; SULFAFURAZOLE; SULFAMETHIZOLE; SULFAMETHOXAZOLE; SULFAMETHOXYPYRIDAZINE; SULFAMONOMETHOXINE; SULFANILAMIDE DERIVATIVE; SULFAPHENAZOLE; SULFASOMIDINE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CRYPTOCOCCUS NEOFORMANS; DILUTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

ANTI-INFECTIVE AGENTS; ASPERGILLUS FUMIGATUS; CRYPTOCOCCUS NEOFORMANS; DRUG RESISTANCE, FUNGAL; MICROBIAL SENSITIVITY TESTS; SULFAMETHOXAZOLE; SULFAPHENAZOLE; SULFUR COMPOUNDS;

ASPERGILLUS; ASPERGILLUS FUMIGATUS; CRYPTOCOCCUS NEOFORMANS VAR. GRUBII;

EID: 33847172799     PISSN: 09164804     EISSN: None     Source Type: Journal    
DOI: 10.3314/jjmm.48.47     Document Type: Article

References (17)

1. Myskowski PL, White MH, Ahkami R: Fungal disease in the immunocompromised host. Dermatol Clin 15: 295-305, 1997.
2. Van Burik JA, Magee PT: Aspect of fungal pathogenesis in humans. Annu Rev Microbiol 55: 743-772, 2001.
3. Latge JP, Calderone R: Host-microbe interactions: fungi. Invasive human fungal opportunistic infections. Opin Microbiol 5: 355-358, 2002.
4. Kwon-Chung KJ, Bennett JE: Cryptococcosis, In Medical Mycology pp.397-446., Lea & Febiger, Philadelphia, PA, 1992.
5. Kiertiburanakul S, Wirojtananugoon S, Pracharktam R, Sungkanuparph S: Cryptococcosis in human immunodeficiency virus-negative patients. Int J Infect Dis 10: 72-78, 2006.
6. Denning DW: Invasive aspergillosis. Clin Infect Dis 26: 781-805, 1998.
7. Hope WW, Denning DW: Invasive aspergillosis: the current and future challenges in diagnosis and therapy. Clin Microbiol Infect 10: 2-4, 2004.
8. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ: In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by clinical and laboratory standards institute broth microdilution methods. J Clin Microbiol 43: 3807-3810, 2005.
9. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT: Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 49: 507-512, 2005.
10. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nubling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E: Voriconazole treatment for less-common, emerging or refractory fungal infections. Clin Infect Dis 36: 1122-1131, 2003.
11. Hida S, Yoshida M, Nakabayashi I, Miura NN, Adachi Y, Ohno N: Anti-fungal activity of sulfamethoxazole toward Aspergillus species. Biol Pharm Bull 28: 773-778, 2005.
12. Carr A, Tindall B, Penny R, Cooper DA: Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. AIDS 6: 165-171, 1992.
13. Hughes WT: Effects of pentamidine isethionate on Saccharomyces cerevisiae. Annu Rev Med 42: 287-295, 1991.
14. Hahn RC, Morato Conceicao YT, Santos NL, Ferreira JF, Hamdan JS: Disseminated paracoccidioidomycosis: correlation between clinical and in vitro resistance to ketoconazole and trimethoprim sulphamethoxazole. Mycoses 46: 342-347, 2003.
15. Scavone R, Burger E: Paracoccidioidomycosis: reduction in fungal load and abrogation of delayed-type hypersensitivity anergy in susceptible inbred mice submitted to therapy with trimethoprim-sulfamethoxazole. Med Microbiol Immunol 193: 53-59, 2004.
16. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Approved Standard. Document M-27A. National Committee for Clinical Laboratory Standards, Wayne, PA. 1997.
17. National Committee for Clinical Laboratory Standards: Reference Method for Broth Dilution Antifungal Susceptibility Testing of Conidium-Forming Filamentous Fungi. Proposed Standard. Document M-38P. National Committee for Clinical Laboratory Standards, Wayne, PA, 1998.